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Buruli ulcer (BU) is an infection of skin
and soft tissue caused by Mycobacterium
ulcerans, a toxin-producing environmental
mycobacterium. Significant advances in
the treatment of BU have been made over
the past decade with the introduction of
effective antibiotic therapy and there is a
greater understanding of the pathogenesis
and host immune response. Although it is
generally held that early BU lesions may
heal spontaneously, to our knowledge,
there are no previously published cases
that definitively document spontaneous
resolution of culture-confirmed BU.
Presentation of Case
The patient was a 72-year-old man
from Melbourne, Australia, who had
visited his holiday house in Point Lons-
dale, an endemic area of BU on the coast
70 km to the southwest [1,2], most
weekends for the past 28 years. He had a
past medical history of coronary artery
disease but was otherwise fit and active. In
October 2008 he noted a 5-week history of
a slowly progressive painless papule with a
punctate centre on his left ankle (Figure 1).
His most recent visit to Point Lonsdale was
2 weeks before the lesion appeared.
The diagnosis of BU was made uncon-
ventionally. The patient’s 12-year-oldgran-
dson was attending a clinic with his mother
for treatment of IS2404 PCR-confirmed
[3] BU on his lower back as reported
elsewhere [4]. During the consultation she
mentioned that her father also had a
progressive lesion on his ankle. She was
given a dry specimen swab to take home
with instructions on how to sample her
father’s ankle lesion. Material from the
ankle swab tested positive for acid-fast
bacilli (AFB) by Ziehl-Neelsen (Z-N) stain-
ing and M. ulcerans infection was confirmed
by PCR and later by culture. A repeat swab
taken by the treating clinician (PDRJ) 2
weeks later was again positive for AFB, and
PCR again confirmed M. ulcerans infection.
Culture from this second specimen was
ultimately negative, although the culture
result was not available at the time
management decisions had to be taken.
Antibiotics were considered but not pre-
scribed [5], as there was a potential
interaction between the patient’s cardiac
medications and rifampicin. Instead, exci-
sion with primary closure was performed
without the use of antibiotics or other
treatment modalities (Figure 1). Sections of
the excised tissue showed a 3-mm area of
skin ulceration (Figure 2, left panel) with
mixed inflammatory cell infiltration and
granulation tissue extending into subcuta-
neous fat (Figure 2, right panel). AFB were
not detected, but the appearances were
considered consistent with M. ulcerans
infection in a healing or resolving phase of
the infection [6]. The excised tissue spec-
imen was divided into five sub-sections and
all portions screened by both PCR and
culture according to standard operating
procedures. Generally, this means that the
entire sub-section of tissue is cut into
smaller pieces and homogenised in a bottle
containing glass beads and 2 ml of phos-
phate buffered saline. If the sub-section is
too large to fit into the bead bottle, smaller
pieces of tissue are taken from throughout
the specimen to maximise the likelihood of
sampling organisms. One ml of tissue
homogenate is then processed for PCR
[3] and 1 ml used for culture in BACTEC
12B bottles and on Brown and Buckle
medium [7] incubated at 31uC for up to 12
weeks.M.ulceranswasno longerdetected by
either method. The patient gave informed
consent for publication.
Case Discussion
Buruli ulcer has an alarming potential
for progressive tissue destruction and has
the potential to leave patients permanently
disabled due to widespread necrosis of
subcutaneous fat, extensive fibrous scar
tissue formation, and contractures [6,8,9].
However, even when no effective therapy is
available, progression may cease [10,11].
The human immune system is therefore
able to contain M. ulcerans, albeit after some
years and considerable tissue destruction.
The details of how this final victory is won
are of great importance to researchers
working on BU vaccines.
Our patient first noted a lesion 5 weeks
before the first diagnostic specimen was
obtained. AFB were seen, IS2404 PCR
was positive, and M. ulcerans was isolated
by culture. The diagnosis was reconfirmed
with a second swab. The lesion was
excised a month later but no AFB were
detectable by then, and both PCR and
culture were negative. Of note, the
patient’s grandson who visited his grand-
father’s house at Point Lonsdale contem-
poraneously developed a large progressive
BU over his lower back [4].
M. ulcerans, like M. tuberculosis and M.
leprae, does not cause clinical disease in all
exposed individuals. Gooding et al. [12]
showed that the prevalence of antibodies
to M. ulcerans in exposed household
controls in Queensland was similar to that
in patients with proven BU using a whole
cell antigen preparation. Similar findings
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Figure 2. Histopathology of excised lesion. Left panel: Section of excised skin ulcer, showing one ulcer margin with fibrinous exudate in the
base of the ulcer. Granulation tissue with a mixed inflammatory cell infiltrate extends into subcutaneous fat (H&E, orig mag640). Right panel: Section
from the base of the ulcer, showing granulation tissue with a mixed inflammatory cell infiltrate. Acid-fast bacilli were not seen in a Z-N stained section
of the same area (H&E, orig mag 6200).
doi:10.1371/journal.pntd.0001290.g002
www.plosntds.org 2 October 2011 | Volume 5 | Issue 10 | e1290with more specific antigens have confirmed
this observation in West Africa [13,14].
However, antibodies to M. ulcerans are not
M. ulcerans specific and are encountered in
persons from endemic and non-endemic
regions, which makes it difficult to evaluate
evidence for spontaneous remission based
on the presence of antibodies. As with most
infectious diseases, variation in host im-
mune response genes is likely to influence
susceptibility. In a study performed in
Ghana, the SLC11A1 (NRAMP1) D543N
polymorphism, which confers susceptibility
to tuberculosis and leprosy, has been linked
to increased susceptibility to BU, with an
estimated 13% population attributable risk
[15].
However, it also likely that inoculum
size influences outcome. For example, our
patient may have received a lower initial
inoculum than his grandson, although the
natural inoculum size has not been
definitively established. Fenner noted that
the protective effect of BCG against M.
ulcerans in a mouse model could be
overcome by increasing the inoculum
[16]. Unlike the grandson, it is also
possible that our patient had a prior
exposure to M. ulcerans that may have
immunised him and enhanced his ability
to control his infection, as he reported very
frequent visits to Point Lonsdale where
transmission of M. ulcerans has been
common since at least 2002 [1,2].
This report of spontaneous clearance of
M. ulcerans from a small but clinically
apparent BU confirms previous anecdotal
and some systematic field observations in
patients likely to have BU, but from whom
definitive laboratory confirmation was not
available [17]. For example, Revill et al.
reported that 29% of patients with small
nodular lesions diagnosed clinically healed
spontaneously while receiving placebo
during a randomised study of clofazamine
therapy [18].
The key virulence factor of M. ulcerans,
mycolactone, has potent cytotoxic and
immunosuppressive properties that act
both locally and systemically. Initially,
the histology of BU lesions shows bland
necrosis with a remarkable absence of an
acute inflammatory response (reviewed in
Schu ¨tte et al. [19]). However, natural
halting of progressive infection, or treat-
ment with antibiotics, appears to be
associated with the development of a
vigorous Th-1 response, the development
of delayed type hypersensitivity to myco-
bacterial antigens, and intense granuloma-
tous inflammation on histology (reviewed
by Demangel et al. [20] and Schu ¨tte et al.
[19]). At present, no satisfactory model
exists to explain how the human host is
able to sterilize active M. ulcerans infections
that are likely to be producing increasing
local concentrations of mycolactone, par-
ticularly as mycolactone itself does not
appear to stimulate the production of
neutralising antibodies [19]. The mecha-
nism by which this occurs will be of great
interest, as a vaccine able to induce this
sterilizing response should be highly effec-
tive for both primary prevention and as an
adjuvant to therapy.
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Key Learning Points
N Some people with confirmed Buruli ulcer are able to spontaneously eradicate
M. ulcerans before they develop destructive lesions.
N This suggests a major role for adaptive immunity in protection against M.
ulcerans infection.
N When new treatments for M. ulcerans are evaluated the possibility of
spontaneous resolution needs to be considered.
www.plosntds.org 3 October 2011 | Volume 5 | Issue 10 | e1290